Evidence map›Paper›PMID 37794178›Full record

ReviewBritish journal of cancer2023

The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.

Jinhai Deng, Teng Pan, Zaoqu Liu, Caitlin McCarthy, Jose M Vicencio, Lulu Cao, Giovanna Alfano, Ali Abdulnabi Suwaidan, Mingzhu Yin, Richard Beatson and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Exploratory transcriptomics andBiomedical reports · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Jinhai Deng *Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Teng Pan *Longgang District Maternity & Child Healthcare Hospital of Shenzhen City (Longgang Maternity and Child Institute of Shantou University Medical College), Shenzhen, 518172, China.
Zaoqu Liu *Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-0452-742X
Caitlin McCarthyRichard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Jose M VicencioRichard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Lulu CaoDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Giovanna AlfanoRichard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Ali Abdulnabi SuwaidanRichard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Mingzhu YinClinical Research Center (CRC), Clinical Pathology Center (CPC), Chongqing University Three Gorges Hospital, Chongqing University, Wanzhou, Chongqing, China.
Richard BeatsonRichard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK. r.beatson@ucl.ac.uk.ORCID 0000-0002-0411-932X
Tony NgRichard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK. tony.ng@kcl.ac.uk.ORCID 0000-0003-3894-5619
King's College London · GBChongqing University · CNBreast Cancer Now · GBCancer Research UK · GBFirst Affiliated Hospital of Zhengzhou University · CNPeking University · CNShantou University · CN

Funding

Cancer Research UK (CRUK) C7675/A29313Cancer Research UK (CRUK) SEBSTF-2021\100007China Scholarship Council (CSC) 201806010012China Scholarship Council (CSC) 202006940028RCUK | Medical Research Council (MRC) MR/R000026/1
6 · The paper itself

Abstract

Thioredoxin-interacting protein (TXNIP) is commonly considered a master regulator of cellular oxidation, regulating the expression and function of Thioredoxin (Trx). Recent work has identified that TXNIP has a far wider range of additional roles: from regulating glucose and lipid metabolism, to cell cycle arrest and inflammation. Its expression is increased by stressors commonly found in neoplastic cells and the wider tumor microenvironment (TME), and, as such, TXNIP has been extensively studied in cancers. In this review, we evaluate the current literature regarding the regulation and the function of TXNIP, highlighting its emerging role in modulating signaling between different cell types within the TME. We then assess current and future translational opportunities and the associated challenges in this area. An improved understanding of the functions and mechanisms of TXNIP in cancers may enhance its suitability as a therapeutic target.

Indexed as

NeoplasmsThioredoxinsCarrier ProteinsGlucoseHumansInflammationOxidation-ReductionTumor MicroenvironmentCarrier ProteinsGlucoseThioredoxinsTXNIP protein, human

Identifiers

PMID37794178
PMCPMC10703902
OpenAlexW4387332005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.